ES-481 / Avalo Therap, ES Therap - LARVOL DELTA

Efficacy and Safety of ES-481, a Novel TARP Inhibitor, in Drug-resistant Epilepsy: A Double-blind Randomized Placebo Controlled Phase IIa Trial (AAN 2024) - P2a | "ES-481 demonstrated evidence of anti-seizure efficacy compared to the placebo in patients with DRE. ES-481 dosing up to 75 mg bid was safe and well tolerated."

Clinical • P2a data • CNS Disorders • Epilepsy • Hematological Disorders

Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy (clinicaltrials.gov) - P2a | N=24 | Recruiting | Sponsor: ES Therapeutics Australia Pty Ltd | Trial completion date: Oct 2022 ➔ Dec 2023 | Trial primary completion date: Mar 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • CNS Disorders • Epilepsy

Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors (clinicaltrials.gov) - P2a | N=24 | Recruiting | Sponsor: ES Therapeutics Australia Pty Ltd | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Essential Tremor • Movement Disorders